




Docket No.: A0871.70001US00
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rong-Hwa Lin et al.
Serial No.: 10/662,906
Confirmation No.: 1268
Filed: September 15, 2003
For: MODULATORS OF P-SELECTIN GLYCOPROTEIN LIGAND 1
Examiner: P. Gambel
Art Unit: 1644

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: <u>March 1, 2007</u>	 Alan W. Steele, M.D., Ph.D., Registration No. 45,128

**REPLY TO NOTICE OF NON-RESPONSIVE REPLY TO RESTRICTION
REQUIREMENT**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication mailed January 19, 2007, which indicates that Applicant's Response to Restriction Requirement mailed on October 31, 2006, was non-responsive, Applicant elects psoriasis as a single disclosed species of inflammatory disease.

Remarks

The Examiner indicated that although Applicant previously elected inflammatory disease, Applicant should elect a single disclosed species of an inflammatory disease (e.g., psoriasis, asthma) as the ultimate species, as indicated in the Restriction Requirement, mailed 10/4/06. Applicant wishes to point out that the Restriction Requirement mailed 10/4/06 appears to indicate Applicant was required to elect a single disclosed species of disease or condition *selected from claims 14-18 or pages 22-23 of the instant application*. Claim 14 specifies